In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day.

CRISPR/Cas9 is a groundbreaking technology for precisely modifying ... Overall CRSP ranks 5th on our list of the best genomics stocks to buy. While we acknowledge the potential of the CRSP as ...

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In ... can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

KBC Group NV lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2,047.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and ...

Shares of CRISPR are up 6% to $43.98 in afternoon trading. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing ...

CRISPR Therapeutics has positioned itself at the forefront of gene editing technology ... InvestingPro data indicates significant stock price volatility with a beta of 1.67, while the company's ...